$ELMD

[144] Electromed, Inc. SEC Filing

This article details an SEC Form 144 filing by Electromed, Inc. (ELMD) concerning a proposed sale of 40,000 shares of common stock with an aggregate market value of $1,419,357.79. The securities were acquired via an option grant on July 1, 2016, and are intended for sale on May 15, 2026, through Fidelity Brokerage Services. The filing indicates a neutral impact and sentiment.

Original reporting
Published May 16, 2026, 3:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 16, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ELMD
Neutral
medium confidence
Mentioned
$ELMD
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ELMDNeutralLow
01

Why it matters

The scheduled sale may lead to a mild decrease in stock price due to increased supply, but the overall impact is expected to be limited given the size relative to trading volume.

02

Market read

The event is company-specific with minimal immediate impact on the broader market or sector.

03

What to watch

Market conditions at the time of sale, overall investor sentiment, and broader economic factors could influence the stock's reaction beyond the filing itself.

Timing: medium

Background

Electromed, Inc. filed SEC Form 144 indicating a planned sale of 40,000 shares acquired via an option grant in 2016, scheduled for May 15, 2026.

Company-level read

Ticker impact

$ELMDNeutralMedium confidence
Context

The SEC Form 144 filing pertains to Electromed, Inc., indicating a planned sale of 40,000 shares acquired via an option grant in 2016, scheduled for May 15, 2026.

Expected impact

Potential slight decrease in stock price around the sale date, approximately 1-3%.

Evidence & confidence

The sale is sizable but scheduled for a future date; market reaction depends on broader market conditions and investor sentiment at that time.

Market effects

Limited sector impact; Electromed operates in a niche medical device market with minimal influence on broader sectors.

Negligible regional effects; the sale is specific to Electromed and does not involve regional market shifts.

Low; the event is company-specific with no immediate global market implications.

Counterpoint

Some investors might interpret the scheduled sale as a sign of management's confidence in future stock performance, viewing it as a liquidity event rather than a negative indicator.

Key entities

  • Electromed, Inc.

    A medical device company specializing in respiratory health solutions.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.